Apogee Therapeutics Inc [APGE] stock prices are up 1.87% to $38.22 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The APGE shares have gain 4.63% over the last week, with a monthly amount glided 1.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apogee Therapeutics Inc [NASDAQ: APGE] stock has seen the most recent analyst activity on September 25, 2025, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $60. Previously, BTIG Research reaffirmed its Buy rating on July 07, 2025, and elevated its price target to $115. On March 13, 2025, Citigroup initiated with a Buy rating and assigned a price target of $95 on the stock. Canaccord Genuity started tracking the stock assigning a Buy rating and suggested a price target of $89 on November 25, 2024. BofA Securities initiated its recommendation with a Buy and recommended $80 as its price target on May 10, 2024. BTIG Research started tracking with a Buy rating for this stock on December 20, 2023, and assigned it a price target of $43. In a note dated August 08, 2023, Wedbush initiated an Outperform rating and provided a target price of $40 on this stock.
The stock price of Apogee Therapeutics Inc [APGE] has been fluctuating between $26.20 and $63.50 over the past year. Currently, Wall Street analysts expect the stock to reach $60 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $38.22 at the most recent close of the market. An investor can expect a potential return of 56.99% based on the average APGE price forecast.
Analyzing the APGE fundamentals
Gross Profit Margin for this corporation currently stands at -4.54% with Operating Profit Margin at -2083.29%, Pretax Profit Margin comes in at -1319.58%, and Net Profit Margin reading is -1319.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.23 and Total Capital is -0.43. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.30 points at the first support level, and at 36.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.70, and for the 2nd resistance point, it is at 39.17.
Ratios To Look Out For
It’s worth pointing out that Apogee Therapeutics Inc [NASDAQ:APGE]’s Current Ratio is 16.36. Also, the Quick Ratio is 16.36, while the Cash Ratio stands at 3.94.
Transactions by insiders
Recent insider trading involved Dambkowski Carl, Chief Medical Officer, that happened on Sep 03 ’25 when 2725.0 shares were sold. Chief Medical Officer, Dambkowski Carl completed a deal on Aug 06 ’25 to sell 2725.0 shares. Meanwhile, Chief Medical Officer Dambkowski Carl sold 10090.0 shares on Jul 02 ’25.
